PG
JAZZ icon

PEAK6 Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

PEAK6 Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-30,276
Closed -$4.43M – 4425
2017
Q3 		$4.43M Buy
30,276
+22,470
+288% +$3.4M 0.02% 823
2017
Q2 		$1.21M Buy
7,806
+7,450
+2,093% +$1.14M 0.01% 1767
2017
Q1 		$52K Buy
+356
New +$46.4K ﹤0.01% 3830
2016
Q3 		– Sell
-2,393
Closed -$323K – 4476
2016
Q2 		$338K Sell
2,393
-20,908
-90% -$3.08M ﹤0.01% 2709
2016
Q1 		$3.04M Buy
23,301
+10,944
+89% +$1.36M 0.02% 899
2015
Q4 		$1.74M Sell
12,357
-22,502
-65% -$3.12M 0.01% 1462
2015
Q3 		$4.63M Buy
+34,859
New +$6M 0.02% 952
2015
Q2 		– Sell
-1,121
Closed -$201K – 5238
2015
Q1 		$194K Sell
1,121
-5,109
-82% -$877K ﹤0.01% 3469
2014
Q4 		$1.02M Buy
6,230
+2,304
+59% +$382K 0.01% 1938
2014
Q3 		$630K Buy
+3,926
New +$604K ﹤0.01% 2266
2014
Q2 		– Sell
-58,133
Closed -$8.06M – 4859
2014
Q1 		$8.06M Buy
+58,133
New +$8.75M 0.07% 369

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

PEAK6 Group's JAZZ Position: Q4 2017 in Review

PEAK6 Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2017, closing a stake of 30,276 shares — an estimated $4.43M sold.

PEAK6 Group first reported a position in JAZZ in Q1 2014 and held it in 11 quarters. The position peaked at $8.06M in Q1 2014. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

  • PEAK6 Group reported no remaining Jazz Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • PEAK6 Group sold 30,276 Jazz Pharmaceuticals shares in Q4 2017, an estimated $4.43M.
  • PEAK6 Group first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • PEAK6 Group's Jazz Pharmaceuticals position peaked at $8.06M in Q1 2014.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on PEAK6 Group's 13F filing for Q4 2017, filed 14 Feb 2018.